blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2233501

EP2233501 - HUMANIZED ANTI-CD34 MONOCLONAL ANTIBODY, THE PREPARATION AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  17.05.2013
Database last updated on 17.07.2024
Most recent event   Tooltip18.07.2014Lapse of the patent in a contracting state
New state(s): HU		published on 20.08.2014  [2014/34]
Applicant(s)For all designated states
Shanghai Guojian Bio-Tech Institute
No.399 Libing Road Zhangjiang High-Tech Park
Shanghai 201203 / CN
[2010/39]
Inventor(s)01 / GUO, Yajun
No.399 Libing Road
Zhangjiang high-tech Park
Shanghai 201203 / CN
02 / QIAN, Weizhu
No.399 Libing Road
Zhangjiang high-tech Park
Shanghai 201203 / CN
03 / HOU, Sheng
No.399 Libing Road
Zhangjiang high-tech Park
Shanghai 201203 / CN
04 / LI, Bohua
No.399 Libing Road
Zhangjiang high-tech Park
Shanghai 201203 / CN
05 / WANG, Hao
No.399 Libing Road
Zhangjiang high-tech Park
Shanghai 201203 / CN
06 / MA, Jing
No.399 Libing Road
Zhangjiang high-tech Park
Shanghai 201203 / CN
 [2012/28]
Former [2010/39]01 / GUO, Yajun
No.399 Libing Road Zhangjiang high-tech Park
Shanghai 201203 / CN
02 / QIAN, Weizhu
No.399 Libing Road Zhangjiang high-tech Park
Shanghai 201203 / CN
03 / HOU, Sheng
No.399 Libing Road Zhangjiang high-tech Park
Shanghai 201203 / CN
04 / LI, Bohua
No.399 Libing Road Zhangjiang high-tech Park
Shanghai 201203 / CN
05 / WANG, Hao
No.399 Libing Road Zhangjiang high-tech Park
Shanghai 201203 / CN
06 / MA, Jing
No.399 Libing Road Zhangjiang high-tech Park
Shanghai 201203 / CN
Representative(s)Høiberg P/S
Adelgade 12
1304 Copenhagen K / DK
[N/P]
Former [2012/28]Høiberg A/S
St. Kongensgade 59 A
1264 Copenhagen K / DK
Former [2010/39]Høiberg A/S
St. Kongensgade 59 A
1264 Copenhagen K / DK
Application number, filing date08865354.803.12.2008
[2010/39]
WO2008CN01963
Priority number, dateCN200719445613.12.2007         Original published format: CN200710094456
CN200814301608.01.2008         Original published format: CN200810043016
[2010/39]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2009079922
Date:02.07.2009
Language:ZH
[2009/27]
Type: A1 Application with search report 
No.:EP2233501
Date:29.09.2010
Language:EN
[2010/39]
Type: B1 Patent specification 
No.:EP2233501
Date:11.07.2012
Language:EN
[2012/28]
Search report(s)International search report - published on:CN02.07.2009
(Supplementary) European search report - dispatched on:EP03.11.2010
ClassificationIPC:C07K16/28, C12P21/08, G01N33/543, A61K39/44, A61P7/06, A61P35/00, C12N15/13, G01N33/574, G01N33/569
[2012/01]
CPC:
G01N33/56972 (EP,US); A61P35/00 (EP); A61P7/06 (EP);
C07K16/2896 (EP,US); G01N33/54326 (EP,US); G01N33/57426 (EP,US);
C07K2317/24 (EP,US); C07K2317/56 (EP,US); C07K2317/565 (EP,US);
C07K2317/76 (EP,US); C07K2317/92 (EP,US); G01N2333/70596 (EP,US);
G01N2800/245 (EP,US) (-)
Former IPC [2010/48]C07K16/28, C12P21/08, G01N33/543, A61K39/44, A61P7/06, A61P35/00, C12N15/13
Former IPC [2010/39]C07K16/28, C12P21/08, G01N33/543, A61K39/44, A61P7/06, A61P35/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/39]
TitleGerman:HUMANISIERTER MONOKLONALER ANTI-CD34-ANTIKÖRPER UND DESSEN HERSTELLUNG UND ANWENDUNGEN[2010/39]
English:HUMANIZED ANTI-CD34 MONOCLONAL ANTIBODY, THE PREPARATION AND USES THEREOF[2010/39]
French:ANTICORPS MONOCLONAL ANTI-CD34 HUMANISÉ, SA PRÉPARATION ET SES UTILISATIONS[2010/39]
Entry into regional phase30.06.2010Translation filed 
13.07.2010National basic fee paid 
13.07.2010Search fee paid 
13.07.2010Designation fee(s) paid 
13.07.2010Examination fee paid 
Examination procedure13.07.2010Examination requested  [2010/39]
29.04.2011Amendment by applicant (claims and/or description)
13.07.2011Despatch of a communication from the examining division (Time limit: M04)
23.11.2011Reply to a communication from the examining division
03.01.2012Communication of intention to grant the patent
27.04.2012Fee for grant paid
27.04.2012Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  13.07.2011
Opposition(s)12.04.2013No opposition filed within time limit [2013/25]
Fees paidRenewal fee
03.01.2011Renewal fee patent year 03
22.11.2011Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU03.12.2008
AT11.07.2012
BE11.07.2012
CY11.07.2012
CZ11.07.2012
DK11.07.2012
EE11.07.2012
FI11.07.2012
HR11.07.2012
IT11.07.2012
LT11.07.2012
LV11.07.2012
MT11.07.2012
NL11.07.2012
PL11.07.2012
RO11.07.2012
SE11.07.2012
SI11.07.2012
SK11.07.2012
TR11.07.2012
BG11.10.2012
NO11.10.2012
GR12.10.2012
ES22.10.2012
IS11.11.2012
PT12.11.2012
GB03.12.2012
IE03.12.2012
LU03.12.2012
CH31.12.2012
LI31.12.2012
MC31.12.2012
FR02.01.2013
[2014/34]
Former [2014/27]AT11.07.2012
BE11.07.2012
CY11.07.2012
CZ11.07.2012
DK11.07.2012
EE11.07.2012
FI11.07.2012
HR11.07.2012
IT11.07.2012
LT11.07.2012
LV11.07.2012
MT11.07.2012
NL11.07.2012
PL11.07.2012
RO11.07.2012
SE11.07.2012
SI11.07.2012
SK11.07.2012
TR11.07.2012
BG11.10.2012
NO11.10.2012
GR12.10.2012
ES22.10.2012
IS11.11.2012
PT12.11.2012
GB03.12.2012
IE03.12.2012
LU03.12.2012
CH31.12.2012
LI31.12.2012
MC31.12.2012
FR02.01.2013
Former [2014/21]AT11.07.2012
BE11.07.2012
CY11.07.2012
CZ11.07.2012
DK11.07.2012
EE11.07.2012
FI11.07.2012
HR11.07.2012
IT11.07.2012
LT11.07.2012
LV11.07.2012
MT11.07.2012
NL11.07.2012
PL11.07.2012
RO11.07.2012
SE11.07.2012
SI11.07.2012
SK11.07.2012
TR11.07.2012
BG11.10.2012
NO11.10.2012
GR12.10.2012
ES22.10.2012
IS11.11.2012
PT12.11.2012
GB03.12.2012
IE03.12.2012
CH31.12.2012
LI31.12.2012
MC31.12.2012
FR02.01.2013
Former [2013/51]AT11.07.2012
BE11.07.2012
CY11.07.2012
CZ11.07.2012
DK11.07.2012
EE11.07.2012
FI11.07.2012
HR11.07.2012
IT11.07.2012
LT11.07.2012
LV11.07.2012
MT11.07.2012
NL11.07.2012
PL11.07.2012
RO11.07.2012
SE11.07.2012
SI11.07.2012
SK11.07.2012
BG11.10.2012
NO11.10.2012
GR12.10.2012
ES22.10.2012
IS11.11.2012
PT12.11.2012
GB03.12.2012
IE03.12.2012
CH31.12.2012
LI31.12.2012
MC31.12.2012
FR02.01.2013
Former [2013/50]AT11.07.2012
BE11.07.2012
CY11.07.2012
CZ11.07.2012
DK11.07.2012
EE11.07.2012
FI11.07.2012
HR11.07.2012
IT11.07.2012
LT11.07.2012
LV11.07.2012
NL11.07.2012
PL11.07.2012
RO11.07.2012
SE11.07.2012
SI11.07.2012
SK11.07.2012
BG11.10.2012
NO11.10.2012
GR12.10.2012
ES22.10.2012
IS11.11.2012
PT12.11.2012
IE03.12.2012
CH31.12.2012
LI31.12.2012
MC31.12.2012
FR02.01.2013
Former [2013/48]AT11.07.2012
BE11.07.2012
CY11.07.2012
CZ11.07.2012
DK11.07.2012
EE11.07.2012
FI11.07.2012
HR11.07.2012
IT11.07.2012
LT11.07.2012
LV11.07.2012
NL11.07.2012
PL11.07.2012
RO11.07.2012
SE11.07.2012
SI11.07.2012
SK11.07.2012
BG11.10.2012
NO11.10.2012
GR12.10.2012
ES22.10.2012
IS11.11.2012
PT12.11.2012
IE03.12.2012
CH31.12.2012
LI31.12.2012
MC31.12.2012
Former [2013/47]AT11.07.2012
BE11.07.2012
CY11.07.2012
CZ11.07.2012
DK11.07.2012
EE11.07.2012
FI11.07.2012
HR11.07.2012
IT11.07.2012
LT11.07.2012
LV11.07.2012
NL11.07.2012
PL11.07.2012
RO11.07.2012
SE11.07.2012
SI11.07.2012
SK11.07.2012
BG11.10.2012
NO11.10.2012
GR12.10.2012
ES22.10.2012
IS11.11.2012
PT12.11.2012
IE03.12.2012
MC31.12.2012
Former [2013/46]AT11.07.2012
BE11.07.2012
CY11.07.2012
CZ11.07.2012
DK11.07.2012
EE11.07.2012
FI11.07.2012
HR11.07.2012
IT11.07.2012
LT11.07.2012
LV11.07.2012
NL11.07.2012
PL11.07.2012
RO11.07.2012
SE11.07.2012
SI11.07.2012
SK11.07.2012
BG11.10.2012
NO11.10.2012
GR12.10.2012
ES22.10.2012
IS11.11.2012
PT12.11.2012
MC31.12.2012
Former [2013/34]AT11.07.2012
BE11.07.2012
CY11.07.2012
CZ11.07.2012
DK11.07.2012
EE11.07.2012
FI11.07.2012
HR11.07.2012
IT11.07.2012
LT11.07.2012
LV11.07.2012
NL11.07.2012
PL11.07.2012
RO11.07.2012
SE11.07.2012
SI11.07.2012
SK11.07.2012
BG11.10.2012
NO11.10.2012
GR12.10.2012
IS11.11.2012
PT12.11.2012
MC31.12.2012
Former [2013/33]AT11.07.2012
BE11.07.2012
CY11.07.2012
CZ11.07.2012
DK11.07.2012
EE11.07.2012
FI11.07.2012
HR11.07.2012
IT11.07.2012
LT11.07.2012
LV11.07.2012
NL11.07.2012
PL11.07.2012
RO11.07.2012
SE11.07.2012
SI11.07.2012
SK11.07.2012
NO11.10.2012
GR12.10.2012
IS11.11.2012
PT12.11.2012
MC31.12.2012
Former [2013/23]AT11.07.2012
BE11.07.2012
CY11.07.2012
CZ11.07.2012
DK11.07.2012
EE11.07.2012
FI11.07.2012
HR11.07.2012
IT11.07.2012
LT11.07.2012
LV11.07.2012
NL11.07.2012
PL11.07.2012
RO11.07.2012
SE11.07.2012
SI11.07.2012
SK11.07.2012
NO11.10.2012
GR12.10.2012
IS11.11.2012
PT12.11.2012
Former [2013/22]AT11.07.2012
BE11.07.2012
CY11.07.2012
CZ11.07.2012
DK11.07.2012
EE11.07.2012
FI11.07.2012
HR11.07.2012
LT11.07.2012
LV11.07.2012
NL11.07.2012
PL11.07.2012
SE11.07.2012
SI11.07.2012
NO11.10.2012
GR12.10.2012
IS11.11.2012
PT12.11.2012
Former [2013/21]AT11.07.2012
BE11.07.2012
CY11.07.2012
DK11.07.2012
FI11.07.2012
HR11.07.2012
LT11.07.2012
LV11.07.2012
NL11.07.2012
PL11.07.2012
SE11.07.2012
SI11.07.2012
NO11.10.2012
GR12.10.2012
IS11.11.2012
PT12.11.2012
Former [2013/15]AT11.07.2012
BE11.07.2012
CY11.07.2012
FI11.07.2012
HR11.07.2012
LT11.07.2012
LV11.07.2012
NL11.07.2012
PL11.07.2012
SE11.07.2012
SI11.07.2012
NO11.10.2012
GR12.10.2012
IS11.11.2012
PT12.11.2012
Former [2013/13]AT11.07.2012
BE11.07.2012
CY11.07.2012
FI11.07.2012
HR11.07.2012
LT11.07.2012
LV11.07.2012
PL11.07.2012
SE11.07.2012
SI11.07.2012
NO11.10.2012
GR12.10.2012
IS11.11.2012
PT12.11.2012
Former [2013/12]AT11.07.2012
BE11.07.2012
CY11.07.2012
FI11.07.2012
HR11.07.2012
LT11.07.2012
LV11.07.2012
PL11.07.2012
SE11.07.2012
SI11.07.2012
NO11.10.2012
GR12.10.2012
IS11.11.2012
Former [2013/11]AT11.07.2012
BE11.07.2012
CY11.07.2012
FI11.07.2012
HR11.07.2012
LT11.07.2012
LV11.07.2012
PL11.07.2012
SI11.07.2012
NO11.10.2012
GR12.10.2012
IS11.11.2012
Former [2013/10]AT11.07.2012
BE11.07.2012
CY11.07.2012
FI11.07.2012
HR11.07.2012
LT11.07.2012
NO11.10.2012
IS11.11.2012
Former [2013/09]AT11.07.2012
BE11.07.2012
FI11.07.2012
LT11.07.2012
NO11.10.2012
Former [2013/08]AT11.07.2012
BE11.07.2012
LT11.07.2012
NO11.10.2012
Former [2013/07]AT11.07.2012
Documents cited:Search[A]EP1083226  (ASAHI CHEMICAL IND [JP], et al) [A] 1-10 * examples 18-20,23,24 * * paragraph [0046] - paragraph [0050] *;
 [A]US2007207210  (BROWN LARRY R [US], et al) [A] 1-10 * example 6 *;
 [IP]  - W. QIAN ET AL., "Development of new versions of anti-human CD34 monoclonal antibodies with potentially reduced immunogenicity.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, U.S.A., (20080307), vol. 367, no. 2, pages 497 - 502, XP027016399 [IP] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.bbrc.2007.12.184
 [XP]  - S. HOU ET AL., "Humanization of an anti-CD34 monoclonal antibody by complementarity-determining region grafting based on computer-assisted molecular modelling.", JOURNAL OF BIOCHEMISTRY, Japan, (200807), vol. 144, no. 1, pages 115 - 120, XP002605633 [XP] 1-10 * the whole document *
International search[YP]CN101245108  (SHANGHAI ZHONGXIN GUOJIAN PHAR [CN]);
 [XP]  - HOU S ET AL., "Humanization of an anti-CD34 monoclonal antibody by complementarity-determining region grafting based on computer-assisted molecular modeling", J BIOCHEM, (200807), vol. 144, no. 1, pages 115 - 120, XP002605633
 [YP]  - QIAN W ET AL., "anti-human CD34 mAb 4C8 immunoglobulin heavy chain variable region ?Mus musculus?", GENBANK, (20080219), Database accession no. ABY61978
 [YP]  - QIAN W ET AL., "anti-human CD34 mAb 4C8 immunoglobulin light chain variable region ?Mus musculus?", GENBANK, (20080219), Database accession no. ABY61979
by applicant   - ANDREWS RG BRYANT EM; BARTELMEZ SH; MUIRHEAD DT; KNITTER GH; BENSINGER W; STRONG DM; BERNSTIEN ID, "CD34+ marrow cells, devoid of T and B Lymphocytes, reconstitute stable lymphopoiesis and myelopoiesis in lethally irradiated baboons", BLOOD, (1992), vol. 80, page 1693
    - SHPALL EJ; JONES RB; FRANKLIN W; BEARMAN S; STEMMER S; HAMI L; PETSCHE D; TAFFS S; MYERS S; PURDY M, "Transplantation of autologous CD34+ hematopoietic progenitor cells into breast cancer patient following high-dose chemotherapy", J CLIN ONCOL, (1994), vol. 12, page 28
    - WINTER G; HARRIS WJ, "Humanized antibodies", IMMUNOL TODAY, (199306), vol. 14, no. 6, pages 243 - 6
    - CELL, (1980), vol. 22, pages 197 - 207
    - NUCLEIC ACIDS RESEARCH, (1982), vol. 10, pages 4071 - 4079
    - LI BH; WANG H; DAI JX; JI JJ; QIAN WZ; ZHANG DP; HOU S; GUO YJ, "Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions", IMMUNOLOGY, (2005), vol. 116, no. 4, doi:doi:10.1111/J.1365-2567.2005.02247.X, pages 487 - 98, XP002600947

DOI:   http://dx.doi.org/10.1111/J.1365-2567.2005.02247.X
    - "Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions", IMMUNOLOGY, (2005), vol. 116, no. 4, pages 487 - 98
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.